SG Americas Securities LLC Has $755,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR)

SG Americas Securities LLC cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHRGet Rating) by 61.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,208 shares of the biotechnology company’s stock after selling 6,833 shares during the period. SG Americas Securities LLC’s holdings in United Therapeutics were worth $755,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Emerald Advisers LLC lifted its holdings in United Therapeutics by 9.4% during the first quarter. Emerald Advisers LLC now owns 203,359 shares of the biotechnology company’s stock worth $36,485,000 after acquiring an additional 17,402 shares in the last quarter. Laurel Wealth Planning LLC bought a new position in United Therapeutics during the first quarter worth about $54,000. Harbor Capital Advisors Inc. bought a new position in United Therapeutics during the first quarter worth about $151,000. DekaBank Deutsche Girozentrale lifted its holdings in United Therapeutics by 2.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 21,280 shares of the biotechnology company’s stock worth $3,834,000 after acquiring an additional 418 shares in the last quarter. Finally, Comerica Bank lifted its holdings in United Therapeutics by 7.2% during the first quarter. Comerica Bank now owns 30,210 shares of the biotechnology company’s stock worth $5,657,000 after acquiring an additional 2,026 shares in the last quarter. 94.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on UTHR shares. HC Wainwright lifted their target price on United Therapeutics from $248.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday, May 24th. Credit Suisse Group lifted their target price on United Therapeutics from $219.00 to $247.00 and gave the stock an “outperform” rating in a report on Tuesday, May 24th. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $225.00 to $238.00 in a report on Tuesday, May 24th. Wedbush boosted their price target on United Therapeutics from $236.00 to $263.00 and gave the company an “outperform” rating in a report on Tuesday, May 24th. Finally, Oppenheimer boosted their price target on United Therapeutics from $275.00 to $300.00 in a report on Thursday, May 5th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $250.14.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $225.30 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.54 and a current ratio of 8.84. The stock’s 50-day simple moving average is $230.57 and its 200 day simple moving average is $202.59. The company has a market cap of $10.21 billion, a P/E ratio of 15.59, a P/E/G ratio of 4.27 and a beta of 0.53. United Therapeutics Co. has a 52-week low of $158.38 and a 52-week high of $245.48.

United Therapeutics (NASDAQ:UTHRGet Rating) last released its earnings results on Wednesday, May 4th. The biotechnology company reported $5.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $2.07. The business had revenue of $461.90 million for the quarter, compared to the consensus estimate of $420.02 million. United Therapeutics had a return on equity of 17.62% and a net margin of 38.87%. United Therapeutics’s quarterly revenue was up 21.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.61 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Co. will post 17.19 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $226.27, for a total value of $1,357,620.00. Following the sale, the executive vice president now owns 36,397 shares of the company’s stock, valued at $8,235,549.19. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other United Therapeutics news, Director Raymond Dwek sold 2,160 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $241.29, for a total transaction of $521,186.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $226.27, for a total value of $1,357,620.00. Following the transaction, the executive vice president now directly owns 36,397 shares in the company, valued at approximately $8,235,549.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,160 shares of company stock valued at $11,856,586. 12.10% of the stock is owned by insiders.

United Therapeutics Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Want More Great Investing Ideas?

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.